Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Kala Pharmaceuticals Inc
KALA | US
0.14
USD-0.02
-11.62%
KALA | US
Loading StockChartView...
About Kala Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
24/04/2026
Close
0.14
Open
0.15
High
0.16
Low
0.14
Kala Pharmaceuticals Inc. a biopharmaceutical company focuses on the discovery development and commercialization of therapies for the treatment of eye diseases. The company's product candidates include KPI-012 which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development product including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Hanes Newco Inc. and changed its name to Kala Pharmaceuticals Inc. in December 2009. Kala Pharmaceuticals Inc. was incorporated in 2009 and is headquartered in Watertown Massachusetts.
View LessKALA | US
Risk
115.7
Sharpe
-0.62
Luna's Score
19/100
Recommendation
Sell
Luna says (KALA | US)
What's Working
Value Stock (Price to Book < 3)
What's not Working
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
High Current Volume and Negative 1-Day Return
Microcap (<300M USD)
Low negative Beta, possible Low Liquidity (< -0.4)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
133.5%1 month
115.7%3 months
121.8%6 months
138.2%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.75
Debt to equity
2.68
Debt to assets
0.60
Ent. to EBITDA
-0.16
Ent. to rev.
0.04
PEG
-
Other Fundamentals
EBITDA
-40.98M
MarketCap
745.92K
MarketCap(USD)
745.92K
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-100.00
Ret. on equity
-248.11
Short ratio
2.43
Short perc.
0.68
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
0.10
Range1M
0.10
Range3M
0.47
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
2.21
Price X volume
999.47K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.16 | 0.53 | Cheaper |
| Ent. to Revenue | 0.04 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.75 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 121.82 | 72.80 | Riskier |
| Debt to Equity | 2.68 | -1.23 | Expensive |
| Debt to Assets | 0.60 | 0.25 | Expensive |
| Market Cap | 745.92K | 3.66B | Emerging |
